Dr. Peter Hotez Tells Congress That Children Died In Coronavirus Vaccine Trials (Video)
[Note: You can follow NoMask.info on twitter here.]
Go to NoMask.info for our main index page, which contains a concise list of medical studies, testimony from medical experts, etc.
In this clip, esteemed coronavirus vaccine expert Doctor Peter Hotez, who works with the Gates Foundation, testifies before U.S. Congress on March 5, 2020 about the risks and potential deaths of coronavirus vaccine. Please save this clip and share it widely.
MARCH 5, 2020 | CLIP OF HOUSE SCIENCE, SPACE, AND TECHNOLOGY COMMITTEE HEARING ON CORONAVIRUS
Dr. Peter Hotez Addressing House Science, Space, and Technology Committee Hearing on Coronavirus, March 5, 2020
"When I say scientific challenge, one of the things we are not hearing a lot about is potential safety problems of coronavirus vaccines. This was first found in the 1960s with respiratory interstitial virus vaccines done in Washington with the NIH and Children's National Medical Center. Some of those kids who got the vaccine did worse and I believe there were two deaths. What happens with certain types of respiratory virus vaccine, to get immunized and when you are exposed to the virus you get this paradoxical enhancement phenomenon. We don't entirely understand the basis of it, that we recognize there's a real problem with certain respiratory virus vaccines. That killed the program for decades and now the Gates foundation is taking it up again, but then we start developing coronavirus vaccines. We noticed laboratory animals that they started to show some of the same pathology that resembled what it happened years earlier. This is going to be problematic..."
On July 26, 2020, Gates was questioned about the very high rate of side effects in the recent vaccine trials, but he tried to minimize the issue.
Even CBS pressures Bill Gates on the topic that almost everyone had side effects. He doesn’t seem to care.— An0maly (@LegendaryEnergy) July 26, 2020
Here is the transcript of the Dr. Hotez testimony on C-Span.
PUBLIC-HEALTH THREATS AND YET WE HAVE NOT SEEN THE EGG FARMER GUYS IN THE VIRUS TAX RUSHING INTO THIS SPACE. WE PARTNERED WITH THE GROUP IN THE BLOOD CENTER AND THE GALVESTON NATIONAL LABORATORY TO TAKE ON THE BIG SCIENTIFIC CHALLENGE OF CORONAVIRUS.
WHEN I SAY SCIENTIFIC CHALLENGE ONE OF THE THINGS WE ARE NOT HEARING A LOT ABOUT HIS POTENTIAL SAFETY PROBLEMS OF CORONAVIRUS VACCINES. THIS WAS FIRST FOUND IN THE 1960s WITH RESPIRATORY INTERSTITIAL VIRUS VACCINES DONE IN WASHINGTON WITH THE NIH AND CHILDREN'S NATIONAL MEDICAL CENTER. SOME OF THOSE KIDS WHO GOT THE VACCINE DID WORSE AND I BELIEVE THERE WERE TWO DEATHS. WHAT HAPPENS WITH CERTAIN TYPES OF RESPIRATORY VIRUS VACCINE TO GET IMMUNIZED AND WHEN YOU ARE EXPOSED TO THE VIRUS TO GET THIS PARADOXICAL ENHANCEMENT PHENOMENON.
WE DON'T ENTIRELY UNDERSTAND THE BASIS OF IT THAT WE RECOGNIZE THERE'S A REAL PROBLEM WITH CERTAIN REST VITTORI VIRUS VACCINES. THAT KILLED THE PROGRAM FOR DECADES AND NOW THE GATES FOUNDATION IS TAKING IT UP AGAIN BUT THEN WE START DEVELOPING CORONAVIRUS VACCINES WE NOTICED LABORATORY ANIMALS THAT THEY STARTED TO SHOW SOME OF THE SAME PATHOLOGY THAT RESEMBLED WHAT IT HAPPENED YEARS EARLIER.
THIS IS GOING TO BE PROBLEMATIC BUT WE COLLABORATED WITH THE GROUP THAT FIGURED OUT HOW TO SOLVE THE PROBLEM SO HE COULD NARROW DOWN TO THE RECENT THERE BONDING. WITH THE RECEPTOR YOU GET PROTECTION AND YOU DON'T GET THAT IN ME AN ENHANCEMENT AND WE WERE REALLY EXCITED ABOUT THAT AND POST IT TO THE NATIONAL INSTITUTE OF ALLERGY AND TEXAS DISEASES.
THEY FUNDED IT AND WE WOUND UP ACTUALLY MAKING AND MANUFACTURING IN COLLABORATION WITH WALTER REED ARMY RESEARCH A FIRST GENERATION SARs VACCINE FOR SARs WAS THE ONE THAT EMERGED IN 2003. THIS NEW ONE OF COURSE WE CALLED THE SARs 2 CORONAVIRUS. WE HAD A MANUFACTURED BUT WE NEVER GOT THE INVESTMENT TO TAKE IT BEYOND THAT. SO THAT WAS REALLY UNFORTUNATE BECAUSE WE HAVE THE VACCINE READY TO GO BUT WE COULDN'T MOVE IT FROM THE CLINIC BECAUSE OF LACK OF FUNDING.
WHEN THE CHINESE STARTED PUTTING UP THE DATA AND ARCHIVES IN JANUARY AND FEBRUARY WE SAW SYMPTOMATOLOGY BETWEEN THE TWO AND REALIZED THAT WE MAY BE SITTING ON A INTERACTIVE CORONAVIRUS VACCINE. WHERE WORKING TO GET THE FUNDING BUT NOW WE HAVE THAT WIDE.
THESE TRIALS ARE NOT GOING TO GO QUICKLY BECAUSE OF THAT IMMUNITY. IT'S GOING TO TAKE TIME. UNFORTUNATELY SOME OF MY COLLEAGUES AND BIOTECH INDUSTRY ARE MAKING INFLATED CLAIMS PRODUCING THIS IN THE NEWSPAPERS WE WILL HAVE THIS VACCINE IN WEEKS BUT WHAT THEY ARE REALLY SAYING IS THEY CAN MOVE EFFECTS INTO CLINICAL TRIAL.
AS WE START VACCINATING VOLUNTEERS ESPECIALLY IN AREAS WHERE WE HAVE COMMUNITY TRANSMISSION WE ARE GOING TO HAVE TO PROCEED VERY CAUTIOUSLY. THEY HAVE A GREAT TEAM IN PLACE AND RESEARCH. THEY ARE AWARE OF THE PROBLEM BUT IT'S NOT GOING TO GO QUICKLY. WE ARE GOING TO HAVE TO FOLLOW THIS SLOWLY AND CAUTIOUSLY TO MAKE CERTAIN WE AREN'T CREATING AN ENHANCEMENT. WE ARE NOW PROJECTING IT AT
*This transcript was compiled from uncorrected Closed Captioning.